In the recent years, mushrooms are distinguished as important natural resources of immunotherapy which can be used as immunomodulating and immunostimulating in the management of some immunodeficiency diseases such as cancer, tumour, HIV, tuberculosis etc. Mushroom of the genus Pleurotus are good sources of several bioactive compounds which are able to augment or complement a desired immune response. Such bioactive compounds are polysaccharopeptides, polysaccharide-proteins, functional proteins (ubiquinone-9, nebrodeolysin, ubiquitin-like peptide and glycoprotein), glucans, proteoglycans and many others. Most of these bioactive compounds follow the immunomodulatory pathway mechanism of polysaccharide (β-glucan) from mushrooms by stimulating activities for both innate and adaptive immune systems. They proliferate and activate innate immune system components such as natural killer (NK) cells, neutrophils, and macrophages, and stimulate cytokines expression and secretion. These cytokines in turn activate adaptive immunity through the promotion of B-cells for antibodies production and stimulation of T-cell differentiation to T helper (Th1 and Th2) cells, which mediate cell and humoral immunities, respectively. In this review, the immunotherapeutic potential of oyster mushroom in relation to bioactive compounds produced is shown and this suggests that the oyster mushrooms are one of the most important natural products and functional foods.
| Published in |
International Journal of Immunology (Volume 3, Issue 2-1)
This article belongs to the Special Issue Immunotherapy |
| DOI | 10.11648/j.iji.s.2015030201.12 |
| Page(s) | 8-20 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2015. Published by Science Publishing Group |
Oyster Mushroom, Immunotherapy, Beta Glucan, Lectin, Polysaccharide
| [1] | American Cancer Society, Cancer Immunotherapy. Medical Rev 2014; p. 19. |
| [2] | FryTJ, MackallCL, T-cell adoptive immunotherapy for acute lymphoblastic leukemia. AmSoc Hematol Educ Program 2013;348−353. |
| [3] | Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity inpatients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850−854. |
| [4] | Cheung NV. Chapter 32: Therapeutic antibodies and immunologic conjugates. In: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 5th ed. Philadelphia, Pa: Elsevier; 2014. |
| [5] | Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314:126−129. |
| [6] | Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (antiPD1) in melanoma. N Engl J Med 2013;369:134−144. |
| [7] | Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711−723. |
| [8] | BakkenJS, BorodyT, Brandt LJ et al. Treating Clostridium difficile infection with fecal microbiota transplantation . Clin Gastroenterol Hepatol 2011; 9 :1044 – 1049. |
| [9] | Colleen RK, Chioma I, Monika Fet al. Fecal Microbiota Transplant for Treatment of Clostridium difficile Infection in Immunocompromised Patients. The Amer J Gastroenterology 2014; 109: 1065-1071. |
| [10] | Azoulay E, Thiéry G, Chevret S, Moreau D, Darmon M, Bergeron A, Yang K, Meignin V, Ciroldi M, Le Gall JR, Tazi A, Schlemmer B.The prognosis ofacute respiratory failure in critically ill cancer patients. Medicine (Baltimore) 2004; 83:360–370. |
| [11] | Thiéry G, Azoulay E, Darmon M, Ciroldi M, De Miranda S, Lévy V, Fieux F, Moreau D, Le Gall JR, Schlemmer B.Outcome of cancer patients considered for intensive care unit admission: a hospital-wide prospective study.J Clin Oncol 2005; 23:4406–4413. |
| [12] | Benoit DD, Vandewoude KH, Decruyenaere JM, Hoste EA, Colardyn FA. Outcome and early prognostic indicators in patients with a hematological malignancy admitted to the intensive care unit for a life-threatening complication.Crit Care Med 2003; 31:104–112. |
| [13] | Canet E, Osman D, Lambert J, Guitton C, Heng AE, Argaud L, Klouche K,Mourad G, Legendre C, Timsit JF, Rondeau E, Hourmant M, Durrbach A,Glotz D, Souweine B, Schlemmer B, Azoulay E. Acute respiratory failure in kidney transplant recipients: a multicenter study.Crit Care 2011; 15:R91. |
| [14] | Lemiale V, Lambert J, Canet E, Mokart D, Pène F, Rabbat A, Kouatchet A,Vincent F, Bruneel F, Gruson D, Chevret S, Azoulay E:A Groupe deRecherche Respiratoire en Réanimation Onco-Hématologique Study. Identifying cancer patients with acute respiratory failure at high risk forintubation and mechanical ventilation.Respir Care2014, doi:10.4187/respcare.02693. |
| [15] | Jeurink PV, Cristina LN, Huub FJS, Harry J W. Immunomodulatory capacity of fungal proteins on thecytokine production of human peripheralblood mononuclear cells. Int Immunopharmacol2008; 8: 1124–1133. |
| [16] | Adebayo EA, Oloke JK, Ayandele AA, Adegunlola CO. Phytochemical, antioxidant and antimicrobial assay of mushroom metabolite from Pleurotus pulmonarius –LAU 09 (JF736658). J Microbiol Biotech Res 2012b; 2 (2):366-374. |
| [17] | Chang ST, Buswell JA. Medicinal mushrooms as prominent source of nutriceuticals for the 21st century. Curr Topics in Nutraceut Res 2003; 1: 257-280. |
| [18] | Adebayo EA, Oloke JK, Majolagbe ON, Ajani RA, Bora TC. Antimicrobial and anti-inflammatory potential of polysaccharide from Pleurotus pulmonarius LAU 09.Afr J Microbiol Res (2012c); 6(13): 3315-3323. |
| [19] | Adebayo EA, Oloke JK, Azeez MA, Omomowo IO, Bora TC. Assessment of the genetic diversity among ten genotypes of Pleurotus (oyster mushroom) using nutrient and mineral compositions. Sci Horticult2014a; 166: 59–64. |
| [20] | Morris HJ, Llauradó G, Gutiérrez A, Lebeque Y, Fontaine R, Beltrán Y, García N, Bermúdez RC, Gaime-Perraud I. Immunomodulating properties of Pleurotus sp. Fruiting bodies powder on cyclophosphamide treated mice. Pro 7th Int Conf Mushr Biol MushrProd 2011; 324-333. |
| [21] | Gregori A, Mirjan S, Jure P.(2007). Cultivation techniques and medicinal properties of Pleurotus spp.Food Technol. Biotechnol. 45:238-249. |
| [22] | Wang JC, Hu SH, Liang ZC, Yeh C J .Optimization for the production of water-soluble polysaccharide from Pleurotus citrinopileatus in submerged culture and its antitumor effect. Appl Microbiol Biotechnol 2005; 67: 759–766. |
| [23] | Rout D, Mondal S, Chakraborty I, Pramanik M, Islam SS.Chemical analysis of a new (1→3)-, (1→6)-branched glucan from anedible mushroom Pleurotus florida. Carbohydr Res 2005; 340:2533-2539. |
| [24] | Sarangi I, Ghosh D, Bhutia SK, Mallick SK, MaitiTK. Anti-tumor and immunomodulating effects of Pleurotus ostreatus mycelia-derived proteoglycans. Int Immunopharmacol 2006; 6:1287-1297. |
| [25] | Refaie FM,Esmat AY, Daba AS, Taha SM. Characterization of polysaccharopeptides from Pleurotus ostreatus mycelium: assessment of toxicity and immunomodulation in vivo. Micol Apl Int 2009; 21:67-75. |
| [26] | Ng TB, Lam SK, Chan SY.A ubiquitin-like peptide from the mushroomPleurotus sajor-cajuexhibitsrelatively potent translation-inhibitory and ribonuclease activities. Peptides 2002; 23: 1361–1365 |
| [27] | Wu G, Bazer FW, Davis TA, Kim SW, Li P, Rhoads JM, Satterfield MC, Smith SB, Spencer TE. Arginine metabolism and nutrition in growth, health and disease. Amino Acids 2009; 37:153–68. |
| [28] | Lee I-S, Ryoo I-J, Kwon K-Y, Ahn JS, Yoo I-D. Pleurone, a novel human neutrophil elastase inhibitor from the fruiting bodies of the mushroom Pleurotus eryngiivar. ferulae. The J Antibiot 2011; 64: 587–589. |
| [29] | Shlyakhovenko V et al. Application of DNA from mushroom Pleurotus ostreatus for cancer biotherapy. a pilot study. Experim Oncol 2006; 28:132-135. |
| [30] | Martínez-Carrera D. Oyster mushrooms. McGraw-Hill Yearbook of Science and Technology. Ed.: M. D. Licker. McGraw-Hill, Inc.,New York. Pp. 242-245. ISBN 0-07-052625-7 (447 pp.)[http://books.mcgraw-hill.com],1999. |
| [31] | Cohen R, Persky L, Hadar Y. Biotechnological applications and potential of wood-degrading mushrooms of the genus Pleurotus. Appl Microbiol Biotechnol 2002; 58:582–594. |
| [32] | Asef MR. Intersterility groups of Pleurotus ostreatus complex in Iran. An Inter J Fungal Biol (2012); 3(2): 147-152. |
| [33] | Hilber O. Die Gattung Pleurotus. Biblioth Mycolog 1982; 87: 448. |
| [34] | Han Yh, Chbn KM, Cheno S. Characteristics and cultivation of a new Pleurotusin Taiwan. Mushr Sci 1974; 9: 167-174. |
| [35] | Bresinsky A, Fischer M, Mbixner B, Paulus W. Speciation in Pleurotus. Mycolog 1987; 79: 234-245. |
| [36] | Jong SC, Peng JT. Identity and cultivation of a new commercial mushroom in Taiwan. Mycolog 1975; 67: 1235-1238. |
| [37] | Moore RT. Mating type factors in Pleurotus cystidiosus. Transactions of the British Mycolog Society 1985; 85: 354-358. |
| [38] | Zervakis G, Labarer J. Taxonomic relationships within the fungal genus Pleurotus as determined by isoelectric focusing analysis of enzyme patterns. J Gen Microbiol1992; 138: 635-645. |
| [39] | Vilgalys R, Smith A, Sun BL, Miller OK. Intersterility groups in the Pleurotus ostreatus complex from the continental United States and adjacent Canada. Canadian J Botany 1993; 71: 113-128. |
| [40] | Vilgalys R, Moncalvo JM, Liou SR, Volovcek M. Recent advances in molecular systematics of the genus Pleurotus. In Mushroom Biology and Mushroom Products, pp. 91–102. Edited by D. J. Royse. Penn State: Penn State University, 1996. |
| [41] | Adebayo EA, Oloke JK, Yadav A, Barooah A, Bora TC. Improving yield performance of Pleurotus pulmonarius through hyphal anastomosis fusion of dikaryons. World J Microbiol Biotechnol 2013; 29:1029–1037. |
| [42] | Adebayo EA, Martínez-Carrera D. Oyster mushrooms (Pleurotus) are useful for utilizing lignocellulosic biomass. Afr J Biotech 2014; (in press). |
| [43] | Royse DJ. Cultivation of oyster mushrooms.College of Agricultural Sciences, Pennsylvania State University, University Park. PA. p. 12, 2003. |
| [44] | Chang ST. World production of cultivated edible and medicinal mushrooms in 1997 With emphasis on Lentinus edodes (Berk.) Sing. in China. Intl J Med Mushr 1999; 1:291-300. |
| [45] | United States Department of Agriculture, Office of Communications. Agriculture Fact Book |
| [46] | 2002; p.169. |
| [47] | Royse DJ, Rhodes TW, Ohga S, Sanchez JE. Yield, mushroom size and time to production of Pleurotus cornucopiae (oyster mushroom) grown on switch grass substrate spawned and supplemented at various rates. Bioresour Technol 2004; 91: 85–91. |
| [48] | Khan MA, Amin SMR, Alam N, Tania M. Study of Mycelial Growth of Cordycepssinensis on Different Culture Media. Bangladesh J Mushr2008; 2: 43-48. |
| [49] | Wasser SP, Weis AL. Medicinal properties of substances occurring in Higher Basidiomycetes mushrooms: current perspectives. Int J Med Mushr 1999; 1:31–62. |
| [50] | Bae J-S, Park JW, Park SH, Park JB, Rho Y-H, Ryu YB, Lee K-S, Park K-H, Bae Y-S. Apoptotic cell death of human leukaemia U937 cells by ubiquinone-9purified fromPleurotus eryngii. Nat Product Res 2009; 23(12): 1112–1119. |
| [51] | Lv H, Kong Y, Yao Q, Zhang B, Leng FW,Bian HJ, Balzarini J, Damme EV, Bao JK. Nebrodeolysin,a novel haemolytic protein from mushroom Pleurotus nebrodensis with apoptosis-inducing and anti-HIV-1effects. Phytomedicine 2009;16: 198-205. |
| [52] | Li YR, Liu QH, Wang HX, Ng TB. A novel lectin with potent antitumor, mitogenic and HIV-1 reverse transcriptase inhibitory activities from the edible mushroom Pleurotus citrinopileatus. Biochim Biophys Acta 2008; 1780: 51–57. |
| [53] | El Enshasy HA, Hatti-Kaul R. Mushroom immunomodulators:unique molecules with unlimited applications. Trends in Biotechnol 2013; 31(12): 668-677. |
| [54] | Borchers AT, Krishnamurthy A, Keen CL, Meyers FJ, Gershwin ME. The immunobiology of mushrooms. Exp Biol Medicine2008; 233: 259–276. |
| [55] | Chen J, Seviour R. Medicinal importance of fungal β-(1-3), (1-6)-glucans. Mycological res 2007; 111: 635–652. |
| [56] | Khan MA, Tania M. Nutritional and Medicinal Importance of Pleurotus Mushrooms: An Overview. Food Rev Inter 2012; 28(3): 313-329. |
| [57] | Gao W, Sun Y, Chen S, Zhang J, Kang J, Wang Y, Wang H, Xia G, Liu Q, Kang Y. Mushroom lectin enhanced immunogenicity of HBV DNA vaccine in C57BL/6 and HBsAg-transgenic mice. Vaccine 2013; 31: 2273– 2280. |
| [58] | Pérez-Martínez AS, Acevedo-Padilla SA, Bibbins-Martínez M, Galván-Alonsoa J, Rosales-Mendoza S. A perspective on the use of Pleurotus for the development of convenient fungi-made oral subunit vaccines. Vaccine 2015; 33: 25–33. |
| [59] | Schepetkin IA, Quinn MT.Botanical polysaccharides: Macrophage immunomodulation and therapeutic potential. Int Immunopharmacol 2006; 6: 317 – 333. |
| [60] | Mizuno T, Saito H, Nishitoba T, Kawagashi H. Antitumoractive substances from mushrooms. Food Rev Int 1995; 11:23–61. |
| [61] | Lindequist U, Niedermeyer TH, Julich WD. The pharmacological potential of mushrooms.Evid Based Complement Alternat Med2005;2: 285-299. |
| [62] | Chihara G, Hamuro J, Maeda Y, Arai Y, FukuokaF. Fractionation and purification of the polysaccharides with marked antitumor activity, especially lentinan, from Lentinus edodes(Berk.) Sing.(an edible mushroom). Cancer Res 1970; 30:2776-2781. |
| [63] | Chihara G. Immunopharmacology of lentinan, a polysaccharide isolated from Lentinus edodes: its applications as ahost defence potentiator. Int J Orient Med 1992;17: 57–77. |
| [64] | Tsukagoshi S, Hashimoto Y, Fujii G, Kobayashi H, Nomoto K, OrituK. Krestin(PSK).Cancer Treatment Rev 1984; 11:131-135. |
| [65] | Kobayashi H, Matsunaga K, Oguchi Y. Antimetastatic effects of PSK (Krestin), a protein-bound polysaccharide obtained from basidiomycetes: an overview. Cancer Epidemiol Biomark Prevention 1995; 4: 275–281. |
| [66] | Yang QY, Hu YJ, Li XY.A New Biological Response Modifier — PSP. In: ShT Chang, JA Buswell, S W Chiu, eds. Proceedings of the First International Conference on Mushroom Biology and Mushroom Products. Hong Kong. 1993; p. 247−259. |
| [67] | Lavi I, Levinson D, Peri I, Tekoah Y, Hadar Y, SchwartzY .Chemical characterization, antiproliferative properties of polysaccharides extracted from Pleurotus pulmonarius mycelium and fruiting bodies. Appl Microbiold Biotechnol 2010; 85(6):1977–1990. |
| [68] | Wasonga CGO,SheilaAO,JosephCM, CharlesOAO.Mushroompolysaccharideextractsdelayprogressionofcarcinogenesisinmice. J Exper Therapeut Oncology 2008; 7: 147-152. |
| [69] | Akanni EO, Oloke JK, Adebayo EA, Ola IO. Antitumour activities of Pleurotus pulmonarius and Pleurotus ostreatus metabolites on N-Nitroso-N-ethylurea induced solid tumour bearing Wister rats. Glob Res J2010; 1(1): 013- 018. |
| [70] | Sun Y, Liu J. Purification, structure and immunobiological activity of a water-solublepolysaccharide from the fruiting body of Pleurotus ostreatus. Biores Technol 2009; 100: 983–986. |
| [71] | Zhang M, Zhu L, Cui SW, Wang Q, Zhou T, Shen H. Fractionation, partial characterization and bioactivity of water-soluble polysaccharides and polysaccharide-protein complexesfromPleurotus geesteranus. Int J Biol Macromol2011; 48: 5–12. |
| [72] | Facchini JM, Endi PA, Charlise A, Regina MMG, Marcia LLS Wisbeck E, Sandra AF. Antitumor activity of Pleurotus ostreatus polysaccharide fractions on Ehrlich tumor and Sarcoma 180. IntJ Biol Macromol 2014; 68: 72–77. |
| [73] | Patel Y, Ram N, Singh VK.Medicinal Properties ofPleurotus species (Oyster Mushroom): A Review. World J Fungal Plant Biol 2012; 3(1): 01-12. |
| [74] | Choi DB, Cha WS, Kang SH, Lee BR.Effect of Pleurotus ferulae Extracts on Viability of Human Lung Cancer and Cervical Cancer Cell Lines. Biotechnol. Bioprocess Eng 2004; 9: 356-361. |
| [75] | Vos AP, M'Rabet L, Stahl B, Boehm G, Garssen J. Immune-modulatory effects and potential working mechanisms oforally applied nondigestible carbohydrates. Crit Rev Immunol 2007; 27: 97-140. |
| [76] | Batbayar S, Lee DH, Kim HW. Immunomodulation of Fungal β-Glucan in Host Defense Signaling by Dectin-1.Biomol Ther 2012; 20(5): 433-445. |
| [77] | Schmid F, Stone BA, McDougall BM, Bacic A, Martin KL, Brownlee RT, Chai E, Seviour RJ. Structure of epiglucan, a highly side-chain/branched (1→3; 1→6)-β-glucan from themicro fungus Epicoccum nigrum Ehrenb.ex Schlecht. Carbohydrate Res 2001; 331: 163–171. |
| [78] | McIntosh M, Stone BA, Stanisich VA. Curdlan and other bacterial (1→3)-β-D-glucans. Appl Microbiol Biotechnol 2005; 68: 163–173. |
| [79] | Seviour RJ, Stasinopoulos SJ, Auer DPF. Production of pullulan and other exopolysaccharides by filamentous fungi. Critical Rev Biotechnol 1992; 12: 279–298. |
| [80] | Klis FM, de Groot P, Hellingwerf K. Molecular organization of the cell wall of Candida albicans. Medical Mycol 2001; 39: 1–8. |
| [81] | Jayus, McDougall BM, Seviour RJ. Purification and characterization of the (1→3)-β-glucanases fromAcremoniumsp.IMI 383068.FEMS Microbiol Lett 2004; 230: 259–264. |
| [82] | Martin KL, McDougall BM, Unkles SE, Seviour RJ. The three β-1,3-glucanases from Acremonium blochiistrain C59 appear tobe encoded by separate genes. Mycological Res 2006; 110: 66–74. |
| [83] | Vetvicka V, Yvin JC. Effects of marine β-1,3 glucan onimmune reactions. Inter Immunopharmacol 2004; 4:721–730. |
| [84] | Brown GD, Gordon S. Immune recognition of fungal β-glucans. Cellular Microbiol 2005; 7: 471–479. |
| [85] | Kurashige S, Akuzawa Y, Endo F. Effects ofLentinus edodes, Grifola frondosa and Pleurotus ostreatus administration on cancer outbreak, and activities of macrophages and lymphocytesin mice treated with a carcinogen, N-butyl-N-butanolnitrosoamine. Immunopharmacol Immunotoxicol 1997; 19: 175–183. |
| [86] | Brown GD, Taylor PR, Reid DM, Willment JA, Williams DL, Martinez-Pomares L, Wong SY, Gordon S. Dectin-1 is a major β-glucan receptor on macrophages. J Exper Medicine 2002; 196: 407–412. |
| [87] | Munz C, Steinman RM, Fujii S. Dendritic cell maturation byinnate lymphocytes: coordinated stimulation of innate and adaptive immunity. J ExperMedicine2005; 202:203–207. |
| [88] | Vetvicka V, Thornton BP, Ross GD. Soluble β-glucan polysaccharide binding to the lectin site of neutrophil or naturalkiller cell complement receptor type 3 (CD11b/CD18) generatesa primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells. J Clinical Investigat I996; 98: 50–61. |
| [89] | Sato M, Sano H, Iwaki D, Kudo K, Konishi M, Takahashi H,Takahashi T, Imaizumi H, Asai Y, Kuroki Y. Direct binding of Toll-like receptor 2 to zymosan, and zymosaninduced NF-kappa B activation and TNF-α secretion are down-regulated by lung collecting surfactant protein A. J Immunol 2003; 171: 417–425. |
| [90] | Young RE, Thompson RD, Larbi KY, La M, Roberts CE, Shapiro SD,Perretti M, Nourshargh S. Neutrophil elastase (NE)-deficient mice demonstrate a nonredundant role for NE inneutrophil migration, generation of proinflammatory mediators, and phagocytosis in response to zymosan particles in vivo. J Immunol 2004; 172: 4493–4502. |
| [91] | Du Z, Kelly E, Mecklenbrauker I, Agle L, Herrero C, Paik P, Ivashkiv LB. Selective regulation of IL-10 signaling andfunction by zymosan.J Immunol.2006; 176: 4785–4792. |
| [92] | Brown GD. Dectin-1: a signalling non-TLR pattern-recognition receptor. Nature Rev Immunol 2006; 6: 33–43. |
| [93] | Zhang M, Zhang L, Wang Y, Cheung PC. Chain conformation of sulfated derivatives of beta-glucan from sclerotia ofPleurotus tuber-regium. Carbohydr Res 2003; 338: 2863–2870. |
| [94] | Manzi P, Pizzoferrato L. Beta-glucans in edible mushrooms. Food Chem 2000;68:315–318. |
| [95] | Bergendiova K, Tibenska E, Majtan J. Pleuran (β-glucan from Pleurotus ostreatus) supplementation, cellular immune response and respiratory tract infections in athletes. Eur J ApplPhysiol 2011; 111: 2033-2040. |
| [96] | Bobovčák M, Kuniaková R, Gabriž J, Majtán J. (2010) Effect of pleuran (β-glucan from Pleurotus ostreatus) supplementation on cellular immune response after intensive exercise in elite athletes. Appl Physiol Nutr Metab 2010; 35: 755-762. |
| [97] | Rovensky J,Stanckova M. Svı´k K, Bauerova´ K, Jurcovicova J. The effects of β-glucan isolated from Pleurotus ostreatus on methotrexate treatment in rats with adjuvant arthritis. Rheumatol Int 2011; 31:507–511. |
| [98] | Jedinak A, Shailesh D, Qing-li W, James S, Daniel S (2011). Anti-inflammatory activity of edible oyster mushroom is mediated through the inhibition of NF-қB and AP-1 signaling. Nutr J 2011; 52: 1-10. |
| [99] | Pramanik M, Mondal S,Chakraborty I, Rout D, Islam SS. Structural investigation of a polysaccharide (Fr. II)isolated from the aqueous extract of an edible mushroom, Pleurotus sajor-caju. Carbohydr Res 2005; 340: 629–636. |
| [100] | Kamilya D,Ghosh D, Bandyopadhyay S, Mal BC, Maiti TK. In vitroeffects of bovine lactoferrin, mushroom glucan and Abrus agglutinin on Indian major carp, catla(Catla catla) head kidney leukocytes. Aquacult 2006; 253: 130–139. |
| [101] | Zhang X, Zhang L, Xu X. Morphologies and conformation transition of Lentinan in aqueous NaOH solution. Biopolymers 2004; 75: 187-195. |
| [102] | Lin WH, Hung CH, Hsu CI, Lin JY. Dimerization of the N-terminalamphipathic alpha-helix domain of the fungal immunomodulatory protein from Ganoderma tsugae (Fip-gts) defined by ayeast two-hybrid system and site-directed mutagenesis. J BiolChem 1997; 272: 20044-20048. |
| [103] | Hsu HC, Hsu CI, Lin RH, Kao CL, Lin JY. Fip-vvo, a new fungal immunomodulatory protein isolated from Volvariella volvacea. Biochem J 1997;323(Pt 2):557-565. |
| [104] | Paaventhan P, Joseph JS, Seow SV, Vaday S, Robinson H, Chua KY. A 1.7 A structure of Fve, a member of the new fungal immunomodulatory protein family. J Mol Biol 2003;332: 461-470. |
| [105] | Ko JL, Hsu CI, Lin RH, Kao CL, Lin JY. A new fungal immunomodulatory protein, FIP-fve isolated from the ediblemushroom,Flammulina velutipesand its complete amino acidsequence. Eur J Biochem 1995; 228:244-249. |
| [106] | Adebayo EA, Oloke JK, Achana Y, Bora TC. Improvement ofLaccase Production in Pleurotus pulmonarius-LAU 09 by Mutation. J Microbiol Res 2012a; 2(1): 11-17. |
| [107] | Chen J-N, Wang Y-T,Wu JS-B.A Glycoprotein Extracted from Golden Oyster Mushroom Pleurotus citrinopileatus Exhibiting Growth Inhibitory Effect against U937 Leukemia Cells. J Agric Food Chem 2009; 57: 6706–6711. |
| [108] | Wu J-Y,Chen C-H, Chang W-H, Chung K-T, Liu Y-W,Lu F-J,Chen C-H. Anti-Cancer Effects of Protein Extracts from Calvatia lilacina, Pleurotus ostreatu sand Volvariella volvacea. Evidence-Based Compl Alter Medicine 2011; doi:10.1093/ecam/neq057. |
| [109] | Nomura H, Inokuchi N, Kobayashi H, Koyama T, Iwama M, Ohgi K. Purification and primary structure of a new guanylic and specific ribonuclease from Pleurotus ostreatus. J Biochem 1994;116:26–33. |
| [110] | Wong JH, Ng TB, Jiang Y, Liu F, Sze SCW, Zhang KY. Purification and Characterization of a Laccase with Inhibitory Activity Toward HIV-1 Reverse Transcriptase and Tumor Cells from an Edible Mushroom (Pleurotus cornucopiae). Prot Pept Lett 2010; 17: 1040-1047. |
| [111] | Wang HX, Ng TB, Ooi VEC.A ribonuclease from sclerotia of the edible mushroom Pleurotus tuber-regium. Biochem Biophys Res Commun 1998;250:544–546. |
| [112] | Wang HX, Ng TB. Isolation and characterization of velutin, a novel low-molecular-weight ribosome-inactivating protein from winter mushroom (Flammulina velutipes) fruiting bodies. Life Sci 2001; 68: 2151-2158. |
| [113] | Wang JB, Wang HX, Ng TB.A peptide with HIV-1 reverse transcriptase inhibitory activity from the medicinal mushroom Russula paludosa. Peptides 2007;28(3): 560-565. |
| [114] | Maiti S, Bhutia SK, Mallick SK, Kumar A, Khadgi N, Maiti TK. Antiproliferative and immunostimulatory protein fraction from edible mushrooms. Environ Toxicol Pharmacol 2008;26(2):187–191. |
| [115] | Peumans WJ,Zhang W,Barre A, Houles CA, Balint-Kurti PJ, Rovira P, Rouge P, May GD, Van LF, Truffa-Bachi P, Van Damme EJM. Fruit-specific lectins from banana and plantain. Planta 2000; 211(4): 546-554. |
| [116] | Loris R, Hamelryck T, Bouckaert J, Wyns L. Legume lectin structure. Biochim et Biophys Acta 1998; 1383(1): 9–36. |
| [117] | She Q-B, Ng T-B, Liu W-K.A novel lectin with potent immunomodulatory activity isolated from both fruiting bodies and cultured mycelia of the edible mushroom Volvariella volvacea. Biochem Biophys Res Comm 1998; 247(1): 106–111. |
| [118] | Wang H, Gao J, Ng T. A new lectin with highly potent antihepatoma and antisarcoma activities from the oyster mushroom Pleurotus ostreatus. BiochemBiophys Res Commun 2000;275(3):810–816. |
| [119] | Wang HX, Ng TB, Liu WK, Ooi VEC, Chang ST. Isolation and characterization of two distinct lectins with antiproliferative activity from the cultured mycelium of the edible mushroomTricholoma mongolicum. Int JPeptide Protein Res 1995; 46: 508-513. |
| [120] | Wang HX, Ng TB, Ooi VEC, Liu WK, Chang ST.A polysaccharide-peptide complex from cultured mycelia of themushroom Tricholoma mongolicumwith immunoenhancing and antitumor activities.Biochem Cell Biol 1996; 74: 95-100. |
| [121] | Li YR, Zhang GQ, Ng TB, Wang HX. A novel lectin with antiproliferative and HIV-1reverse transcriptase inhibitory activities from dried fruiting bodies of themonkey head mushroomHericium erinaceum. J Biomed Biotechnol 2010; doi:10.1155/2010/716515. |
| [122] | Rana T, Asit KB, Subhashree D, Debasis B, Diganta P,Samiran B, Dipak KM, Srikanta S, Subhasish B, Subrata KD. Pleurotus floridalectin normalizes duration dependent hepatic oxidative stressresponses caused by arsenic in rat. Exper Toxicologic Pathol 2012; 64: 665–671. |
| [123] | Mostafavi H, Mohammad-Fata M, Shirin G, Ghorban-Ali H. Immunomodulating and anticancer agents in the realm ofmacromycetes fungi (macrofungi). Int Immunopharmacol 2007; 7: 701–724. |
| [124] | Ivanova TS, Krupodorova TA, Barshteyn VY, Artamonova AB, Shlyakhovenko VA.Anticancer Substances of Mushroom Origin.Exp Oncol 2014; 36(2): 58–66. |
| [125] | Bok JW, Lermer L, Chilton J.Antitumor sterols fromthe mycelia of Cordyceps sinensis. Phytochem 1999; 51: 891−898. |
| [126] | Jedinak A, Sliva D. Pleurotus ostreatus inhibits proliferation of human breast and colon cancer cells through p53-dependent as well as p53-independent pathway. Int J Oncol 2008; 33(6): 1307–1313. |
| [127] | Martin KR, Brophy SK. Commonly consumed and specialty dietary mushrooms reducecellular proliferation in MCF-7 human breast cancer cells. Exper Biol Medicine2010;235: 1306–1314. |
| [128] | Jedinak A, Dudhgaonkar S, Jiang J, Sandusky G, Sliva D. Pleurotus ostreatusinhibits colitis-relatedcolon carcinogenesis in mice. Inter J Molecul Medicine 2010; 26: 643-650. |
| [129] | Gu YH, Leonard J. In vitro effects on proliferation, apoptosis and colony inhibition in ER-dependent and ER-independent human breast cancer cells by selected mushroom species. Oncol Rep2006;15:417–423. |
| [130] | Kim JH, Kim SJ, Park HR, Choi JI, Ju YC, Nam KC, Kim SJ, Lee SC. The different antioxidant and anticancer activities depending on the color of oyster mushrooms. J Med Plants Res 2009; 3: 1016-1020. |
| [131] | Takei T, Yoshida MB, Ohnishi-Kameyama M. Ergosterol peroxide, an apoptosis-inducing component isolated from Sarcodon aspratus (Berk.) S. Ito. Biotech Biochem2005; 69: 212−215. |
| [132] | Liu Y-W, Mei H-C, Su Y-W, Fan H-T, Chen C-C, Tsai Y-C. Inhibitory effects of Pleurotus tuber-regium mycelia and bioactive constituents on LPS-treated RAW264.7 cells. J Functional Foods 2014; 7: 662–670. |
APA Style
Oloke J. K., Adebayo E. A. (2015). Effectiveness of Immunotherapies from Oyster Mushroom (Pleurotus species) in the Management of Immunocompromised Patients. International Journal of Immunology, 3(2-1), 8-20. https://doi.org/10.11648/j.iji.s.2015030201.12
ACS Style
Oloke J. K.; Adebayo E. A. Effectiveness of Immunotherapies from Oyster Mushroom (Pleurotus species) in the Management of Immunocompromised Patients. Int. J. Immunol. 2015, 3(2-1), 8-20. doi: 10.11648/j.iji.s.2015030201.12
AMA Style
Oloke J. K., Adebayo E. A. Effectiveness of Immunotherapies from Oyster Mushroom (Pleurotus species) in the Management of Immunocompromised Patients. Int J Immunol. 2015;3(2-1):8-20. doi: 10.11648/j.iji.s.2015030201.12
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.iji.s.2015030201.12,
author = {Oloke J. K. and Adebayo E. A.},
title = {Effectiveness of Immunotherapies from Oyster Mushroom (Pleurotus species) in the Management of Immunocompromised Patients},
journal = {International Journal of Immunology},
volume = {3},
number = {2-1},
pages = {8-20},
doi = {10.11648/j.iji.s.2015030201.12},
url = {https://doi.org/10.11648/j.iji.s.2015030201.12},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.iji.s.2015030201.12},
abstract = {In the recent years, mushrooms are distinguished as important natural resources of immunotherapy which can be used as immunomodulating and immunostimulating in the management of some immunodeficiency diseases such as cancer, tumour, HIV, tuberculosis etc. Mushroom of the genus Pleurotus are good sources of several bioactive compounds which are able to augment or complement a desired immune response. Such bioactive compounds are polysaccharopeptides, polysaccharide-proteins, functional proteins (ubiquinone-9, nebrodeolysin, ubiquitin-like peptide and glycoprotein), glucans, proteoglycans and many others. Most of these bioactive compounds follow the immunomodulatory pathway mechanism of polysaccharide (β-glucan) from mushrooms by stimulating activities for both innate and adaptive immune systems. They proliferate and activate innate immune system components such as natural killer (NK) cells, neutrophils, and macrophages, and stimulate cytokines expression and secretion. These cytokines in turn activate adaptive immunity through the promotion of B-cells for antibodies production and stimulation of T-cell differentiation to T helper (Th1 and Th2) cells, which mediate cell and humoral immunities, respectively. In this review, the immunotherapeutic potential of oyster mushroom in relation to bioactive compounds produced is shown and this suggests that the oyster mushrooms are one of the most important natural products and functional foods.},
year = {2015}
}
TY - JOUR T1 - Effectiveness of Immunotherapies from Oyster Mushroom (Pleurotus species) in the Management of Immunocompromised Patients AU - Oloke J. K. AU - Adebayo E. A. Y1 - 2015/02/07 PY - 2015 N1 - https://doi.org/10.11648/j.iji.s.2015030201.12 DO - 10.11648/j.iji.s.2015030201.12 T2 - International Journal of Immunology JF - International Journal of Immunology JO - International Journal of Immunology SP - 8 EP - 20 PB - Science Publishing Group SN - 2329-1753 UR - https://doi.org/10.11648/j.iji.s.2015030201.12 AB - In the recent years, mushrooms are distinguished as important natural resources of immunotherapy which can be used as immunomodulating and immunostimulating in the management of some immunodeficiency diseases such as cancer, tumour, HIV, tuberculosis etc. Mushroom of the genus Pleurotus are good sources of several bioactive compounds which are able to augment or complement a desired immune response. Such bioactive compounds are polysaccharopeptides, polysaccharide-proteins, functional proteins (ubiquinone-9, nebrodeolysin, ubiquitin-like peptide and glycoprotein), glucans, proteoglycans and many others. Most of these bioactive compounds follow the immunomodulatory pathway mechanism of polysaccharide (β-glucan) from mushrooms by stimulating activities for both innate and adaptive immune systems. They proliferate and activate innate immune system components such as natural killer (NK) cells, neutrophils, and macrophages, and stimulate cytokines expression and secretion. These cytokines in turn activate adaptive immunity through the promotion of B-cells for antibodies production and stimulation of T-cell differentiation to T helper (Th1 and Th2) cells, which mediate cell and humoral immunities, respectively. In this review, the immunotherapeutic potential of oyster mushroom in relation to bioactive compounds produced is shown and this suggests that the oyster mushrooms are one of the most important natural products and functional foods. VL - 3 IS - 2-1 ER -
Email: